Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
…, H Van Oyen, C Wyndham-Thomas… - International journal of …, 2020 - Elsevier
Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19
across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium…
across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium…
[HTML][HTML] Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium
…, T Braeye, H Van Oyen, C Wyndham-Thomas… - Viruses, 2022 - mdpi.com
The objective of this study was to investigate the incidence and risk factors associated with
COVID-19 vaccine breakthrough infections. We included all persons ≥18 years that had …
COVID-19 vaccine breakthrough infections. We included all persons ≥18 years that had …
[HTML][HTML] Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021
…, S Quoilin, H Van Oyen, C Wyndham-Thomas… - Vaccine, 2021 - Elsevier
In Belgium, high-risk contacts of an infected person were offered PCR-testing irrespective of
their vaccination status. We estimated vaccine effectiveness (VE) against infection and …
their vaccination status. We estimated vaccine effectiveness (VE) against infection and …
Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study
S Desmet, K Lagrou, C Wyndham-Thomas… - The Lancet Infectious …, 2021 - thelancet.com
Background Ten-valent and 13-valent pneumococcal conjugate vaccines (PCVs) have
shown important benefits by decreasing invasive pneumococcal disease caused by vaccine …
shown important benefits by decreasing invasive pneumococcal disease caused by vaccine …
[HTML][HTML] Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis
…, R Verstraete, E Willems, C Wyndham-Thomas - ESMO open, 2020 - Elsevier
Background Cancer seems to have an independent adverse prognostic effect on COVID-19-related
mortality, but uncertainty exists regarding its effect across different patient subgroups…
mortality, but uncertainty exists regarding its effect across different patient subgroups…
[HTML][HTML] Rapid establishment of a national surveillance of COVID-19 hospitalizations in Belgium
N Van Goethem, A Vilain, C Wyndham-Thomas… - Archives of Public …, 2020 - Springer
Background In response to the COVID-19 epidemic, caused by a novel coronavirus, it was
of great importance to rapidly collect as much accurate information as possible in order to …
of great importance to rapidly collect as much accurate information as possible in order to …
[HTML][HTML] Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021
…, N Hammami, D Van Cauteren, C Wyndham-Thomas - Vaccine, 2022 - Elsevier
Background During the first half of 2021, we observed high vaccine effectiveness (VE)
against SARS-CoV2-infection. The replacement of the alpha-‘variant of concern’ (VOC) by the …
against SARS-CoV2-infection. The replacement of the alpha-‘variant of concern’ (VOC) by the …
[HTML][HTML] Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021–2022
…, N Hammami, D Van Cauteren, C Wyndham-Thomas - Vaccine, 2023 - Elsevier
Objectives Vaccine effectiveness against transmission (VET) of SARS-CoV-2-infection can be
estimated from secondary attack rates observed during contact tracing. We estimated VET, …
estimated from secondary attack rates observed during contact tracing. We estimated VET, …
Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities
A Hoxha, C Wyndham-Thomas, S Klamer… - The Lancet Infectious …, 2021 - thelancet.com
As of July 1, Belgium has 61 509 confirmed cases of severe acute respiratory syndrome
corona virus 2 (SARS-CoV-2) infection and 9754 related deaths. In early April, the ministry of …
corona virus 2 (SARS-CoV-2) infection and 9754 related deaths. In early April, the ministry of …
[HTML][HTML] COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022
…, M Vandromme, C Wyndham-Thomas… - …, 2023 - eurosurveillance.org
Background The Belgian COVID-19 vaccination campaign aimed to reduce disease spread
and severity. Aim We estimated SARS-CoV-2 variant-specific vaccine effectiveness against …
and severity. Aim We estimated SARS-CoV-2 variant-specific vaccine effectiveness against …